• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Effective, indicated--and yet without benefit? The goals of dementia drug treatment and the well-being of the patient].

作者信息

Synofzik Matthis

机构信息

Institut für Ethik und Geschichte in der Medizin, Universität Tübingen, Tübingen, Germany.

出版信息

Z Gerontol Geriatr. 2006 Aug;39(4):301-7. doi: 10.1007/s00391-006-0390-6.

DOI:10.1007/s00391-006-0390-6
PMID:16900451
Abstract

Individual treatment decisions for patients with Alzheimer dementia are often characterized by uncertainty about the actual benefit that specific treatments or procedures may bring about. It often even remains unclear how the benefit of a treatment may be determined. In this paper, three criteria for determining the benefit of a treatment measure are developed: An intervention (1) must be effective and (2) able to achieve a clinically relevant goal, which is (3) desirable for the individual patient. By using example of anti-dementia drug treatment, it will by shown that even if standard goals of dementia care are achieved, the benefit for the patient may still be questionable. A cognitive improvement or a delay of cognitive decay may even harm the patient. Therefore it is not sufficient to focus on the efficacy of a drug and on general goals of care when making decisions about individual dementia treatments. Rather it is necessary to reflect and discuss explicitly the goals of the individual patient. As shown by various examples, this will facilitate coherent, patient-orientated treatment decisions.

摘要

相似文献

1
[Effective, indicated--and yet without benefit? The goals of dementia drug treatment and the well-being of the patient].
Z Gerontol Geriatr. 2006 Aug;39(4):301-7. doi: 10.1007/s00391-006-0390-6.
2
Current issues in dementia pharmacotherapy.痴呆症药物治疗的当前问题。
Am J Manag Care. 2007 Dec;13 Suppl 8:S198-202.
3
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.专家共识指南系列。痴呆及其行为障碍的治疗。引言:方法、评论与总结。
Postgrad Med. 2005 Jan;Spec No:6-22.
4
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.与痴呆相关的激越、攻击行为和精神病的管理:一项汇总分析,包括三项在接受利培酮治疗的疗养院居民中进行的随机、安慰剂对照双盲试验。
Clin Neurol Neurosurg. 2005 Oct;107(6):497-508. doi: 10.1016/j.clineuro.2005.03.013.
5
Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.痴呆症神经精神症状的药物治疗:证据综述
J Am Med Dir Assoc. 2006 Mar;7(3):201-2. doi: 10.1016/j.jamda.2005.12.024. Epub 2006 Feb 7.
6
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.利培酮治疗阿尔茨海默病和混合性痴呆所致精神病的疗效和安全性:4项安慰剂对照临床试验的荟萃分析。
Int J Geriatr Psychiatry. 2007 May;22(5):475-84. doi: 10.1002/gps.1792.
7
Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.阿尔茨海默病所致痴呆和轻度认知障碍的药物治疗。
Curr Opin Psychiatry. 2011 Nov;24(6):556-61. doi: 10.1097/YCO.0b013e32834b7b96.
8
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.用于治疗痴呆相关行为的非典型抗精神病药物:最新进展
Med Health R I. 2007 Jun;90(6):191-4.
9
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].[阿尔茨海默病性痴呆。胆碱酯酶抑制剂与银杏的疗效比较]
MMW Fortschr Med. 2001 Dec 13;143(51-52):40-1.
10
Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs.照护者的经历与文献中提出的问题相符吗?与抗痴呆药物相关的伦理问题。
Int J Geriatr Psychiatry. 2006 Sep;21(9):869-75. doi: 10.1002/gps.1576.

引用本文的文献

1
[Tube-feeding in advanced dementia. An evidence-based ethical analysis].[晚期痴呆症患者的管饲。基于证据的伦理分析]
Nervenarzt. 2007 Apr;78(4):418-28. doi: 10.1007/s00115-006-2245-1.

本文引用的文献

1
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.用于阿尔茨海默病患者的胆碱酯酶抑制剂:随机临床试验的系统评价
BMJ. 2005 Aug 6;331(7512):321-7. doi: 10.1136/bmj.331.7512.321.
2
Using rapid-cycle quality improvement methodology to reduce feeding tubes in patients with advanced dementia: before and after study.采用快速循环质量改进方法减少晚期痴呆患者的饲管使用:前后对照研究
BMJ. 2004 Aug 28;329(7464):491-4. doi: 10.1136/bmj.329.7464.491.
3
Evidence-based pharmacotherapy of Alzheimer's disease.
阿尔茨海默病的循证药物治疗
Int J Neuropsychopharmacol. 2004 Sep;7(3):351-69. doi: 10.1017/S1461145704004444. Epub 2004 Jul 1.
4
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.565例阿尔茨海默病患者的长期多奈哌齐治疗(AD2000):随机双盲试验。
Lancet. 2004 Jun 26;363(9427):2105-15. doi: 10.1016/S0140-6736(04)16499-4.
5
AD2000: donepezil in Alzheimer's disease.AD2000:多奈哌齐治疗阿尔茨海默病
Lancet. 2004 Jun 26;363(9427):2100-1. doi: 10.1016/S0140-6736(04)16533-1.
6
Memantine for patients with Alzheimer disease.美金刚用于治疗阿尔茨海默病患者。
JAMA. 2004 Apr 14;291(14):1695; author reply 1695. doi: 10.1001/jama.291.14.1695-a.
7
Donepezil for dementia due to Alzheimer's disease.多奈哌齐用于治疗阿尔茨海默病所致痴呆。
Cochrane Database Syst Rev. 2003(3):CD001190. doi: 10.1002/14651858.CD001190.
8
Percutaneous endoscopic gastrostomy does not prolong survival in patients with dementia.经皮内镜下胃造口术并不能延长痴呆患者的生存期。
Arch Intern Med. 2003 Jun 9;163(11):1351-3. doi: 10.1001/archinte.163.11.1351.
9
The relationship between severity of dementia and subjective well-being.痴呆严重程度与主观幸福感之间的关系。
Aging Ment Health. 2001 May;5(2):191-6. doi: 10.1080/13607860120038375.
10
Tube feeding and advanced progressive dementia.鼻饲与晚期进行性痴呆
Hastings Cent Rep. 2001 Jan-Feb;31(1):36-42.